Blood-Based Cancer Early Detection Testing - Current Clinician Perspectives

DeciBio conducted 12 interviews with U.S. clinicians and healthcare professionals to understand how blood EDx testing is being clinically adopted, to identify key regulatory and commercial barriers to broader use, to define the excitement around single and multi-cancer early detection (MCED) tests, and to collect vendor feedback from current users. Several stakeholders were early adopters of these blood EDx tests and were able to provide first-hand accounts of their experiences so far, including what they perceive as strengths vs. weaknesses with current and emerging EDx test vendors. All stakeholders were able to give advice on benchmarks they'd need to see from regulatory agencies, payers, and professional societies for these tests to see broad adoption in their patient populations.

‍

This report is organized around the responses to 13 key study questions

• How is blood EDx testing currently used in your clinical setting?
• What has been your overall experience (e.g. positive or negative) adopting blood screening tests into the clinic?
• What are the top unmet needs related to overall cancer screening today?
• What are the top barriers to expanded EDx blood testing?
• What are your perspectives on Single-Cancer Early Detection (SCED) vs Multi-Cancer Early Detection (MCED) test methods?
• What’s the workup after a positive EDx blood test, especially in instances when there is no screening guideline?
• What are factors could help ensure successful organize-wide / enterprise-level adoption of blood EDx tests?
• On average, what is the maximum out-of-pocket (OOP) amount patients are willing to pay for cancer screening?
• What are some key trends you think are most / least likely to occur related to EDx testing?
• What near-term (~12 month) changes do you expect in how you conduct cancer screening?
• What are the top blood EDx companies / vendors you are familiar with?
• What is your level of satisfaction and how do you perceive the strengths / weaknesses blood EDx companies?
• What are key ways blood EDx vendors are able to differentiate from one another?

‍

Companies Discussed

• Adela
• Delfi
• Exact Sciences
• Freenome
• GRAIL
• Guardant Health

‍

This advisory board is meant to be a qualitative, limited scope study, and the intent is to highlight the unbiased and unfiltered feedback just from the stakeholders interviewed, not provide a comprehensive market assessment. DeciBio also has a suite of comprehensive market reports (Link Here) if broader industry level insights are of interest. 

‍